Nasdaq:RCEL
AVITA Medical, Inc.
A US-based medical device innovator providing advanced electrosurgical systems to hospitals and ambulatory surgery centers worldwide.
Key Metrics
Investment Thesis
Bull Case
Investors may favor RCEL for its dominant position in a niche electrosurgical market with recurring revenue potential from disposable instrument sales and OEM licensing. The company's strong revenue growth trend from $34.4M to $71.6M over five years demonstrates successful product adoption and market expansion capabilities. Potential acquisition targets or partnerships could provide an exit strategy for shareholders given the high barriers to entry in surgical energy technology.
Bear Case
The bear case centers on persistent profitability issues with net losses deepening to -$61.8M in 2024 before slightly recovering to -$48.6M, raising concerns about long-term sustainability without further dilution. High operating expenses of $101.3M relative to $71.6M revenue suggest inefficient cost management or an extended product development cycle that may not yield expected returns. The negative shareholders' equity of -$16.6M and significant current liabilities of $62.7M indicate potential liquidity stress if market access or financing conditions deteriorate.
About AVITA Medical, Inc.
AVITA Medical (RCEL) designs and manufactures advanced electrosurgical generators, medical devices, and software solutions primarily for the surgical energy market. The company serves hospitals, ambulatory surgery centers, and OEMs globally with its proprietary technology focused on hemostasis and tissue sealing. Recent annual revenue reached $71.6M in 2025, reflecting strong top-line growth despite ongoing net losses.
Analysis
Management Discussion
While revenue grew 11% year-over-year to $71.6M, net income remained negative at $48.6M, driven by substantial operating expenses totaling $101.3M and significant R&D investments of $20.8M. The company maintained a healthy cash position with $10.2M in cash and equivalents but saw a net change in cash of -$3.8M due to heavy investment outflows. Share issuances of $14.8M provided necessary capital injection, though the accumulated deficit widened to -$408.4M, highlighting the need for improved profitability metrics.
Industry Overview
The global medical device industry, particularly the surgical energy sector, is experiencing robust growth driven by aging populations and increased adoption of minimally invasive procedures. Competition remains fierce among established players like Ethicon and newer entrants, with pricing power eroding as hospitals demand higher value propositions. Regulatory scrutiny regarding safety and efficacy continues to be a key factor influencing market entry strategies for innovative technologies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $34.4M | $50.1M | $64.3M | $71.6M |
| Cost of Revenue | $6.0M | $7.8M | $9.1M | $12.8M |
| Gross Profit | $28.4M | $42.4M | $55.2M | $58.8M |
| Operating Expenses | $59.1M | $86.4M | $111.8M | $101.3M |
| Operating Income | $-27.5M | $-42.7M | $-56.6M | $-42.5M |
| R&D | $13.9M | $20.8M | $20.4M | $20.8M |
| G&A | $23.3M | $28.3M | $33.2M | $27.4M |
| Marketing | $21.9M | $37.3M | $58.2M | $53.1M |
| Stock-Based Comp | $7.0M | $8.4M | $13.5M | $9.5M |
| D&A | $568.0K | $632.0K | $1.1M | $2.3M |
| Depreciation | $510.0K | $597.0K | $1.0M | $1.6M |
| Amortization | $58.0K | $35.0K | $93.0K | $600.0K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $876.0K | $7.3M | $-5.2M | $-6.0M |
| Interest Expense | $16.0K | $1.1M | $5.4M | $5.0M |
| Pre-Tax Income | $-26.6M | $-35.3M | $-61.8M | $-48.6M |
| Income Tax | $36.0K | $66.0K | $54.0K | $11.0K |
| Continuing Ops | $-26.7M | $-35.4M | $-61.8M | $-48.6M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-26.7M | $-35.4M | $-61.8M | $-48.6M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-26.7M | $-35.4M | $-61.8M | $-48.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $87.5M | $104.0M | $57.0M | $35.5M |
| Cash & Equivalents | $18.2M | $22.1M | $14.1M | $10.2M |
| Marketable Securities | $61.2M | $66.9M | $21.8M | $7.9M |
| Accounts Receivable | $3.5M | $7.7M | $11.8M | $9.1M |
| Inventory | $2.1M | $5.6M | $7.3M | $6.9M |
| Prepaid Expenses | $1.6M | $1.7M | $2.0M | $1.3M |
| Other Current Assets | $898.0K | $30.0K | $56.0K | $0 |
| Long-Term Assets | $10.8M | $7.6M | $22.7M | $20.9M |
| PP&E (Net) | $1.2M | $1.9M | $10.0M | $8.6M |
| Intangibles | $465.0K | $487.0K | $5.6M | $5.6M |
| Operating Leases | $851.0K | $2.4M | $3.6M | $2.9M |
| LT Securities | $6.9M | — | — | — |
| Other LT Assets | $1.4M | $2.8M | $3.6M | $3.7M |
| Total Assets | $98.3M | $111.6M | $79.7M | $56.4M |
| Current Liabilities | $10.7M | $13.2M | $20.2M | $62.7M |
| Current Debt | — | — | — | $43.0M |
| Current Leases | $612.0K | $895.0K | $900.0K | $929.0K |
| Other Current Liab | $10.1M | $12.3M | $19.3M | $18.8M |
| Long-Term Liabilities | $2.3M | $48.7M | $54.8M | $10.4M |
| Long-Term Debt | — | $39.8M | $42.2M | $0 |
| LT Operating Leases | $306.0K | $1.7M | $2.8M | $2.1M |
| Other LT Liab | $1.3M | $6.8M | $9.4M | $7.9M |
| Total Liabilities | $13.0M | $61.9M | $75.0M | $73.0M |
| Shareholders' Equity | $84.7M | $49.1M | $4.5M | $-16.6M |
| Paid-In Capital | $339.8M | $350.0M | $367.6M | $394.4M |
| Retained Earnings | $-262.6M | $-298.0M | $-359.8M | $-408.4M |
| AOCI | $7.6M | $-1.9M | $-1.9M | $-1.4M |
| Total L&E | $98.3M | $111.6M | $79.7M | $56.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-26.7M | $-35.4M | $-61.8M | $-48.6M |
| Non-Cash Adjustments | $5.0M | $-9.8M | $9.5M | $16.7M |
| Working Capital Changes | $2.6M | $7.1M | $3.4M | $736.0K |
| Cash from Operations | $-19.1M | $-38.0M | $-48.9M | $-31.2M |
| Capital Expenditures | $452.0K | $1.4M | $9.2M | $1.0M |
| Cash from Investing | $-19.3M | $1.6M | $37.4M | $12.5M |
| Debt Issuances | — | $38.8M | — | — |
| Cash from Financing | $900.0K | $40.4M | $3.5M | $14.9M |
| FX Effect | $-26.0K | $-16.0K | $0 | $0 |
| Net Change in Cash | $-37.5M | $4.0M | $-8.1M | $-3.8M |
| Beginning Cash | $55.7M | $18.2M | $22.1M | $14.1M |
| Ending Cash | $18.2M | $22.1M | $14.1M | $10.2M |
Frequently Asked Questions
How does AVITA Medical, Inc. make money?
The company derives revenue from the sale of electrosurgical generators, disposable surgical instruments, and integrated software platforms. Additional streams include licensing agreements with original equipment manufacturers (OEMs) and service contracts for medical facility maintenance. Product lines span both open-market direct sales to healthcare providers and channel distribution through third-party distributors.
What are the main risks for RCEL?
Sustained net losses of $48.6M in 2025 indicate high burn rates that could deplete cash reserves if revenue growth slows or financing conditions tighten. The medical device industry faces intense price pressure from value-based purchasing reforms and potential government reimbursement cuts for elective procedures. High dependence on a limited number of large hospital accounts creates concentration risk, while regulatory delays in bringing new products to market could disrupt the growth trajectory.
What is RCEL's competitive advantage?
AVITA holds a significant market share in the specialized electrosurgical generator segment, leveraging high barriers to entry due to FDA clearance requirements and extensive clinical validation data. The company benefits from a robust intellectual property portfolio protecting its proprietary waveform technology which offers superior hemostasis efficiency. Its direct-to-hospital sales model allows for tighter control over pricing strategies and rapid deployment of software updates compared to competitors relying solely on third-party distribution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.